Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The Merck integrase inhibitor, raltegravir, was studied in two identical trials in different geographic locations to evaluate its safety and efficacy vs placebo in combination with optimized background therapy in patients infected with 3-drug class-resistant (3DCR) HIV-1.

Raltegravir Treatment for Antiretroviral-resistant HIV Infection